CalciMedica Eyes Success In Pancreatitis, Acute Kidney Injury

Phase IIb data for Auxora in an acute pancreatitis subpopulation is expected to set up the CRAC channel inhibitor for Phase III in that indication while suggesting positive read-through for AKI.

Pancreatitis
CalciMedica hopes Auxora can be the first US drug therapy for acute pancreatitis • Source: Shutterstock

More from Clinical Trials

More from R&D